FIELD: oncology.
SUBSTANCE: invention relates to medicinal kit and using Ecteinascidin-743 (Et-743) as well as a method of treating cancer in human patients involving intravenous infusion of composition containing Et-743 to patient suffering from cancer. Intravenous infusion is carried out continuously over a period of up to 4 h and is repeated weakly in Et-743 dose 650 μg/m2/weak. Such weakly infusions represent a phase of infusion cycle. Next phase in the same cycle is repose phase, which is not longer than infusion phase.
EFFECT: improved Et-743 administration mode in cancerous patients minimizing toxicity without loss in desired antitumor effect.
18 cl, 10 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED APPLICATION OF ECTEINASCIDIN-743 AND PLATINUM-CONTAINING ANTI-TUMOUR COMPOUNDS | 2004 |
|
RU2391101C2 |
| PEGYLATED LIPOSOMAL DOXORUBICINUM IN COMBINATION WITH ECTEINESCIDIN 743 | 2005 |
|
RU2359700C2 |
| COMPOSITION AND UTILIZATION OF ET743 FOR MALIGNANT TUMOR TREATMENT | 2000 |
|
RU2266734C2 |
| TREATMENT OF MALIGNANT TUMOR WITH APLIDINE | 2000 |
|
RU2261104C2 |
| KAHALALIDE F | 2001 |
|
RU2292216C2 |
| APPLYING EPOTILONES FOR CANCER TREATMENT | 1999 |
|
RU2242229C2 |
| NOVEL ANTITUMOR COMPOUNDS | 2003 |
|
RU2356908C2 |
| APPLICATIONS OF IMMUNOCONJUGATES, THE TARGET OF WHICH IS CD138 | 2012 |
|
RU2632108C2 |
| COMBINATION THERAPY USING LIPOSOMAL IRINOTECAN AND PARP INHIBITOR FOR THE TREATMENT OF CANCER | 2016 |
|
RU2760185C2 |
| EFFICACY OF CONJUGATES OF ANTI-TROP-2 ANTIBODY WITH DRUG SN-38 FOR THERAPY OF RECURRENT/REFRACTORY TO INHIBITORS OF TUMOR CONTROL POINT | 2017 |
|
RU2725292C2 |
